Skip to main content
The Egyptian Journal of Bronchology
Download PDF
  • Original article
  • Open access
  • Published:

Blood eosinophils and C-reactive protein as prognostic factors in severe chronic obstructive pulmonary disease exacerbations

Egyptian Journal of Bronchology volume 13, pages 605–609 (2019)Cite this article

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Exacerbations of COPD are heterogeneous and have significant effect on the socioeconomic burden. The value of eosinophils (Eos) in predicting response to corticosteroids is documented in bronchial asthma exacerbation, but this value is not clear in COPD exacerbation. The aim of the study is to assess the prognostic value of blood Eos and C-reactive protein (CRP) in severe COPD exacerbations.

Patients and methods

A total of 120 patients with COPD with severe exacerbations were subjected to complete blood count picture analysis with differential count, including Eos and CRP. Cases were divided into eosinophilic and nonesinophilic groups using 2% as a threshold, and the outcomes were observed.

Results

The inpatient mortality rate was 10%, and it significantly correlated with noneosinophilic group (≤2%) (P=0.02). The length of stay in hospital and ICU was significantly lower in patients with eosinophilia more than or equal to 2%, with P value less than 0.001 for both. CRP and length of stay in hospital and ICU showed significant positive correlation.

Conclusion

Higher blood Eos and lower CRP levels can be used as predictors for better outcome in severe COPD exacerbations.

References

  1. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182:693–718.

    Article  Google Scholar 

  2. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867–874.

    Article  CAS  Google Scholar 

  3. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: Just another biomarker? Lancet Respir Med 2017; 5:747–759.

    Article  CAS  Google Scholar 

  4. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662–671.

    Article  Google Scholar 

  5. Gao P, Zhang J, He X, Hao Y, Wang K, Gibson PG. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One 2013; 8:e57678.

    Article  CAS  Google Scholar 

  6. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250–255.

    Article  CAS  Google Scholar 

  7. O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61:1112–1120.

    Article  Google Scholar 

  8. From the Global Strategy for the Diagnosis. Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org. [Accessed 15 June 2018].

  9. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715–1721.

    Article  Google Scholar 

  10. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130:133–142.

    Article  Google Scholar 

  11. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23:698–702.

    Article  CAS  Google Scholar 

  12. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608–1613.

    Article  CAS  Google Scholar 

  13. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847–852.

    Article  CAS  Google Scholar 

  14. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001; 164:358–364.

    Article  CAS  Google Scholar 

  15. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97:S51–S59.

    Article  Google Scholar 

  16. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163:1180–1186.

    Article  Google Scholar 

  17. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J 2016; 47:113–121.

    Article  Google Scholar 

  18. Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax 2012; 67:117–121.

    Article  Google Scholar 

  19. Roberts CM, Barnes S, Lowe D, Pearson MG. Evidence for a link between mortality in acute COPD and hospital type and resources. Thorax 2003; 58:947–949.

    Article  CAS  Google Scholar 

  20. Zeiger RS, Tran TN, Butler RK, Schatz M, Li Q, Khatry DB, et al. Relationship of blood eosinophil count to exacerbations in chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract 2018; 6:944–954.

    Article  Google Scholar 

  21. Villalobos R, Magallanes J, David-Wang A. P143 Blood eosinophilia as predictor for patient outcomes in COPD exacerbations: a systematic review and meta-analysis. Thorax 2016; 71:A160.

    Article  Google Scholar 

  22. Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 2016; 150:320–328

    Article  Google Scholar 

  23. Salturk C, Karakurt Z, Adiguzel N, Kargin F, Sari R, Celik ME, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis 2015; 10:1837–1846.

    Article  CAS  Google Scholar 

  24. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186:48–55.

    Article  CAS  Google Scholar 

  25. Pahuja S, Yadav P, Gautam AK, Kumar A, Kumar A, Chaudhri S. Study of serum C-reactive protein levels in acute exacerbations of chronic obstructive pulmonary disease patients. Int J Med Sci Public Health 2016; 5:694–699.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Diseases, Faculty of Medicine, Cairo University, Giza, 11562, Egypt

    Hamed A. Hafiz MD & Heba Moussa

Authors
  1. Hamed A. Hafiz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heba Moussa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hamed A. Hafiz MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hafiz, H.A., Moussa, H. Blood eosinophils and C-reactive protein as prognostic factors in severe chronic obstructive pulmonary disease exacerbations. Egypt J Bronchol 13, 605–609 (2019). https://doi.org/10.4103/ejb.ejb_42_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_42_19

Keywords